|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer显示文摘 | W.Yu G. S.Choi H. Y.Chung | 2006 | Br J Surg2006，，5： | 3 |
| 2 | Informed and Uninformed Trading in an Electronic, Order‐Driven Environment显示文摘 | PaulBrockman Dennis Y.Chung | 2005 | Financial Review2005，，2： | 2 |
| 3 | Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer显示文摘 | W.Yu G. S.Choi H. Y.Chung | 2006 | Br J Surg2006，，5： | 1 |
| 4 | Serum soluble E‐cadherin is a potential prognostic marker in esophageal squamous cell carcinoma显示文摘 | Y.Chung S.Law D. L. W.Kwong J. M.Luk | 2011 | Diseases of the Esophagus2011，，1： | 1 |
| 5 | Benefit and distance functions显示文摘 | Chambers R.G Y.Chung R.F?re | | 0，，： | 1 |
| 6 | Informed and Uninformed Trading in an Electronic, Order‐Driven Environment显示文摘 | PaulBrockman Dennis Y.Chung | 2005 | Financial Review2005，，2： | 1 |
| 7 | Investor Protection and Firm Liquidity显示文摘 | PaulBrockman Dennis Y.Chung | 2003 | The Journal of Finance2003，，2： | 1 |
| 8 | Benefit and distance functions显示文摘 | R.G.Chambers Y.Chung R.F(a)re | | 0，，02： | 1 |
| 9 | Commonality in Liquidity: Evidence from an Order‐Driven Market Structure显示文摘 | PaulBrockman Dennis Y.Chung | 2002 | Journal of Financial Research2002，，4： | 1 |
| 10 | The Opportunity Cost of Admission Preferences at Elite Universities显示文摘 | Thomas J.Espenshade Chang Y.Chung | 2005 | Social Science Quarterly2005，，2： | 1 |
| 11 | Informed and Uninformed Trading in an Electronic, Order‐Driven Environment显示文摘 | PaulBrockman Dennis Y.Chung | 2005 | Financial Review2005，，2： | 1 |
| 12 | Basophile:Accurate Fragment Charge State Prediction Improves Peptide Identification Rates显示文摘In shotgun proteomics, database search algorithms rely on fragmentation models to predict fragment ions that should be observed for a given peptide sequence. The most widely used strategy (Naive model) is oversimplified, cleaving all peptide bonds with equal probability to produce fragments of all charges below that of the precursor ion. More accurate models, based on fragmentation simulation, are too computationally intensive for on-the-fly use in database search algorithms. We have created an ordinal-regression-based model called Basophile that takes fragment size and basic residue distribution into account when determining the charge retention during CID/higherenergy collision induced dissociation (HCD) of charged peptides. This model improves the accuracy of predictions by reducing the number of unnecessary fragments that are routinely predicted for highly-charged precursors. Basophile increased the identification rates by 26% (on average) over the Naive model, when analyzing triply-charged precursors from ion trap data. Basophile achieves simplicity and speed by solving the prediction problem with an ordinal regression equation, which can be incorporated into any database search software for shotgun proteomic identification. | Dong Wang Surendra Dasari Matthew C.Chambers Jerry D.Holman Kan Chen Daniel C.Liebler Daniel J.Orton Samuel O.Purvine Matthew E.Monroe Chang Y.Chung Kristie L.Rose David L.Tabb | 2013 | Genomics, Proteomics & Bioinformatics2013，11，2： | 0 |
| 13 | 儿童鸡蛋过敏接种流感疫苗的安全性显示文摘目的目前指南建议,鸡蛋过敏患者接种流感疫苗前需做皮试。本研究对鸡蛋过敏儿童分量接种流感疫苗,省略皮试的安全性进行评估。方法我们对年龄6~18岁,鸡蛋过敏患者接受疫苗皮试剂量1/2分次接种流感疫苗进行了病例回顾研究。2002—2003和2006—2007流感季节间,鸡蛋过敏患者在接种流感疫苗前都做了疫苗皮试。从2006—2007年始,我们从草案中取消了皮试,对鸡蛋过敏患者分2次剂量接种流感疫苗。观察所有接种了疫苗患者有否副作用发生。结果 261例鸡蛋过敏患者做了流感疫苗接种评价,171例接受了流感疫苗接种,其中56例接种前做了皮试,95%[95%CI(85.1,98.9)]对疫苗耐受,未发生严重的副作用。从草案中取消皮试后,这个率并未发生变化。其中115例未曾做过皮试接受疫苗患者,有97%[95%CI(91.3,99.0)]对疫苗耐受而未发生副作用。耐受比率为1.01[95%CI(0.97,1.06)]。结论我们的研究结果显示,未发生鸡蛋过敏反应的鸡蛋过敏患者,接受1/2剂量分次接种流感疫苗是安全的,无需做皮试。 | Erica Y.Chung Lin Huang Lynda Schneider 周淑新(译) | 2010 | 中国全科医学2010，13，31： | 0 |
| 14 | Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro显示文摘Objective:Pancreatic cancer(PC)is an aggressive cancer with ineffective treatment.Inhibition of stearoyl-CoA desaturase 1(SCD1)suppresses cancer proliferation and might act as a novel chemotherapy supplement,but this has not been investigated in PC.Here,the effects of SCD1 inhibitor CAY10566 supplemented with gemcitabine treatment(gemcitabine+CAY10566)on PC cell viability,apoptosis,phenotype,fatty acid content,platelet-derived growth factor release,and cell size were investigated.Methods:Human PC cell line(PANC-1)was treated with SCD1 inhibitor CAY10566 with or without gemcitabine.Cell viability was assayed using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide and apoptosis and phenotype were determined using flow cytometry.Fatty acid content and platelet-derived growth factor release were measured by enzyme-linked immunosorbent assay.Cell size was determined using scanning electron microscopy.Results:Half-maximal inhibitory concentration of gemcitabine or CAY10566 significantly reduced PANC-1 viability compared to gemcitabine alone(P<0.0001).No significant differences in the phenotype of phosphatidylserine,tissue factor or basigin expression were detected at therapeutic doses(P>0.05).Apoptosis was significantly increased following incubation with CAY10566(P<0.05).Fatty acid content of cells was significantly higher following gemcitabine treatment compared to CAY10566 alone or gemcitabine+CAY10566(P<0.05).Platelet-derived growth factor released by gemcitabine-treated cells was significantly increased compared to 142 nM CAY10566 alone or gemcitabine+CAY10566(P<0.01).CAY10566 did not affect the size of isolated tumor cells but gemcitabine+CAY10566 significantly increased the size compared to the control(P<0.05).Cell viability decreased significantly after the treatment with gemcitabine+CAY10566 compared with CAY10566 alone(P<0.05)and gemcitabine alone(P<0.01).However,when cycles of chemotherapy were mimicked and treatment was removed,the number of cell viability was significantly reduced(P<0.05).Conclusion:This study suggests that CAY10566 may be a suitable supplement for gemcitabine chemotherapy for PC. | Amon B.Hackney Wen Y.Chung John Isherwood Ashley R.Dennison Naomi Martin | 2021 | Journal of Pancreatology2021，4，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员